טוען...
Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIV(mac251) Acquisition
The recombinant ALVAC vaccine coupled with the monomeric gp120/alum protein have decreased the risk of HIV and SIV acquisition. Ab responses to the V1/V2 regions have correlated with a decreased risk of virus acquisition in both humans and macaques. We hypothesized that the breadth and functional pr...
שמור ב:
| הוצא לאור ב: | J Immunol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
AAI
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5026031/ https://ncbi.nlm.nih.gov/pubmed/27591322 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1600674 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|